Scott M Brittain
Overview
Explore the profile of Scott M Brittain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
965
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosen H, Li K, Li E, Currier B, Brittain S, Garcia F, et al.
bioRxiv
. 2025 Mar;
PMID: 40060528
While MYC is a significant oncogenic transcription factor driver of cancer, directly targeting MYC has remained challenging due to its intrinsic disorder and poorly defined structure, deeming it "undruggable." Whether...
2.
Skakuj K, Iglhaut M, Shao Q, Garcia F, Huang B, Brittain S, et al.
Angew Chem Int Ed Engl
. 2024 Nov;
64(4):e202415976.
PMID: 39509590
Controlled modifications of amino acids are an indispensable tool for advancing fundamental and translational research based on peptides and proteins. Yet, we still lack methods to chemically modify each naturally...
3.
Li J, Canham S, Wu H, Henault M, Chen L, Liu G, et al.
Nat Chem Biol
. 2023 Oct;
20(3):365-372.
PMID: 37828400
Stimulator of interferon genes (STING) is a dimeric transmembrane adapter protein that plays a key role in the human innate immune response to infection and has been therapeutically exploited for...
4.
Henning N, Manford A, Spradlin J, Brittain S, Zhang E, McKenna J, et al.
J Am Chem Soc
. 2023 Sep;
145(38):21142.
PMID: 37708357
No abstract available.
5.
Toriki E, Papatzimas J, Nishikawa K, Dovala D, Frank A, Hesse M, et al.
ACS Cent Sci
. 2023 Aug;
9(8):1702.
PMID: 37637749
[This corrects the article DOI: 10.1021/acscentsci.2c01317.].
6.
Toriki E, Papatzimas J, Nishikawa K, Dovala D, Frank A, Hesse M, et al.
ACS Cent Sci
. 2023 May;
9(5):915-926.
PMID: 37252349
Targeted protein degradation with molecular glue degraders has arisen as a powerful therapeutic modality for eliminating classically undruggable disease-causing proteins through proteasome-mediated degradation. However, we currently lack rational chemical design...
7.
Page A, Scholz S, Keenan K, Spradlin J, Belcher B, Brittain S, et al.
Chem Sci
. 2022 Apr;
13(13):3851-3856.
PMID: 35432890
Photoaffinity labeling (PAL) is a powerful tool for the identification of non-covalent small molecule-protein interactions that are critical to drug discovery and medicinal chemistry, but this approach is limited to...
8.
Henning N, Boike L, Spradlin J, Ward C, Liu G, Zhang E, et al.
Nat Chem Biol
. 2022 Feb;
18(4):412-421.
PMID: 35210618
Many diseases are driven by proteins that are aberrantly ubiquitinated and degraded. These diseases would be therapeutically benefited by targeted protein stabilization (TPS). Here we present deubiquitinase-targeting chimeras (DUBTACs), heterobifunctional...
9.
Salvi A, Young A, Huntsman A, Pergande M, Korkmaz M, Rathnayake R, et al.
Cell Death Dis
. 2022 Jan;
13(1):45.
PMID: 35013112
PHY34 is a synthetic small molecule, inspired by a compound naturally occurring in tropical plants of the Phyllanthus genus. PHY34 was developed to have potent in vitro and in vivo...
10.
Henning N, Manford A, Spradlin J, Brittain S, Zhang E, McKenna J, et al.
J Am Chem Soc
. 2022 Jan;
144(2):701-708.
PMID: 34994556
Proteolysis-targeting chimeras (PROTACs), heterobifunctional compounds that consist of protein-targeting ligands linked to an E3 ligase recruiter, have arisen as a powerful therapeutic modality for targeted protein degradation (TPD). Despite the...